文献速递眼底病与葡萄膜炎

贝伐珠单抗、雷珠单抗和阿柏西普玻璃体腔注射后全身不良事件风险的真实世界比较

Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice.
PubMed 文献 · Ophthalmology · 2020-08-08

采用倾向评分加权Cox比例风险模型比较三种抗VEGF药物在治疗开始后180天内的预设全身结局,发现贝伐珠单抗、雷珠单抗和阿柏西普在急性心肌梗死、急性脑血管病、大出血和全因住院风险上均无差异。

要点

  • 倾向评分加权Cox模型显示各药物两两比较的风险比均无统计学显著性(P>0.05)。
  • 常规临床实践中三种抗VEGF药物的全身安全性未见差异。

核心结论

  • 常规临床实践中,玻璃体腔注射贝伐珠单抗、雷珠单抗或阿柏西普后,急性心肌梗死、脑血管病、大出血或全因住院风险无差异。

研究设计与样本

  • 采用倾向评分加权Cox比例风险模型比较治疗开始后180天内的预设全身结局。

主要发现

  • 注射后180天每100例患者的事件率:贝伐珠单抗组MI 0.64、CVD 0.59、大出血0.34、全因住院10.41;雷珠单抗组分别为0.62、0.53、0.40、9.44;阿柏西普组分别为0.63、0.60、0.20、9.88。
  • 贝伐珠单抗 vs 雷珠单抗:MI HR 0.96(95%CI 0.74-1.25),CVD HR 1.04(95%CI 0.78-1.38),大出血 HR 0.85(95%CI 0.61-1.19),全因住院 HR 1.03(95%CI 0.96-1.10),均P>0.05。
  • 贝伐珠单抗 vs 阿柏西普:MI HR 0.95(95%CI 0.68-1.33),CVD HR 0.99(95%CI 0.71-1.38),大出血 HR 1.02(95%CI 0.60-1.74),全因住院 HR 1.01(95%CI 0.93-1.10),均P>0.05。
  • 阿柏西普 vs 雷珠单抗:MI HR 0.91(95%CI 0.62-1.35),CVD HR 1.12(95%CI 0.74-1.69),大出血 HR 0.96(95%CI 0.53-1.73),全因住院 HR 1.02(95%CI 0.92-1.13),均P>0.05。

关键数值与推荐

  • 主要结局为急性心肌梗死、急性脑血管病、大出血和全因住院,观察窗口为治疗开始后180天。
  • 患者在接受不同抗VEGF药物或健康计划覆盖终止时删失。

临床怎么用

  • 在常规临床实践中选择贝伐珠单抗、雷珠单抗或阿柏西普时,无需因全身安全性差异而优先选择某种药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intravitreal anti-vascular endothelial growth factor (VEGF) pharmacotherapy plays a central role in the management of neovascular age-related macular degeneration (nAMD), diabetic retinal disease (DRD), and retinal venous occlusive disease (RVO). Within clinical trials, rates of systemic serious adverse events (SAEs) after anti-VEGF treatment have been low. However, the comparative systemic safety profile of common anti-VEGF agents remains incompletely understood. The goal of this study was to compare the systemic safety of intravitreal bevacizumab, ranibizumab, and aflibercept in real-world practice. DESIGN: Retrospective cohort study. PARTICIPANTS: Using a large U.S. administrative claims database of commercially insured and Medicare Advantage enrollees, we identified adult cohorts receiving initial anti-VEGF injections for nAMD, DRD, and RVO between January 1, 2007, and June 30, 2018. We included patients with 1 year of insurance coverage before initial treatment. METHODS: We compared predefined systemic outcomes between anti-VEGF agents occurring within 180 days of treatment initiation using propensity score-weighted Cox proportional hazards models. Patients were censored upon treatment with a different anti-VEGF medication or termination of health plan coverage. MAIN OUTCOME MEASURES: Primary outcomes were acute myocardial infarction (MI), acute cerebrovascular disease (CVD), major bleeding, and all-cause hospitalization. RESULTS: A total of 87 844 patients received initial anti-VEGF injections for nAMD, DRD, and RVO between January 1, 2007, and June 30, 2018 (69 007 bevacizumab; 10 895 ranibizumab; 7942 aflibercept). Postinjection 180-day event rates per 100 patients for MI, CVD, major bleeding, and all-cause hospitalization were similar for bevacizumab (0.64, 0.59, 0.34, and 10.41, respectively), ranibizumab (0.62, 0.53, 0.40, and 9.44, respectively), and aflibercept (0.63, 0.60, 0.20, and 9.88, respectively). No differences were identified for the risk of MI, CVD, major bleeding, or all-cause hospitalization when comparing the risk-adjusted effect of treatment initiation with bevacizumab versus ranibizumab (hazard ratio [HR], 0.96 [95% confidence interval {CI}, 0.74-1.25]; HR, 1.04 [95% CI, 0.78-1.38]; HR, 0.85 [95% CI, 0.61-1.19]; HR, 1.03 [95% CI, 0.96-1.10], all P > 0.05), bevacizumab versus aflibercept (HR, 0.95 [95% CI, 0.68-1.33], HR, 0.99 [95% CI, 0.71-1.38], HR, 1.02 [95% CI, 0.60-1.74], HR, 1.01 [95% CI, 0.93-1.10], all P > 0.05), or aflibercept versus ranibizumab (HR, 0.91 [95% CI, 0.62-1.35], HR, 1.12 [95% CI, 0.74-1.69], HR, 0.96 [95% CI, 0.53-1.73], HR, 1.02 [95% CI, 0.92-1.13], all P > 0.05). CONCLUSIONS: We observed no differences in the risk of acute MI, CVD, major bleeding, or all-cause hospitalization after treatment initiation with intravitreal bevacizumab, ranibizumab, or aflibercept during routine clinical practice.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Maloney MH, Payne SR, Herrin J, et al. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice. Ophthalmology. 2020. PMID: 32781110. doi:10.1016/j.ophtha.2020.07.062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。